Related references
Note: Only part of the references are listed.Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review
Neha Singh et al.
CANCER DRUG RESISTANCE (2021)
Small molecule tyrosine kinase inhibitors in glioblastoma
Gayoung Kim et al.
ARCHIVES OF PHARMACAL RESEARCH (2020)
Receptor tyrosine kinase targeting in glioblastoma: performance, limitations and future approaches
Oana Alexandru et al.
WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY (2020)
Broad-spectrum receptor tyrosine kinase inhibitors overcome de novo and acquired modes of resistance to EGFR-targeted therapies in colorectal cancer
Ramona Graves-Deal et al.
Oncotarget (2019)
The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma
Xuejiao Liu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
DECIPHER pooled shRNA library screen identifies PP2A and FGFR signaling as potential therapeutic targets for diffuse intrinsic pontine gliomas
Kathrin Schramm et al.
NEURO-ONCOLOGY (2019)
Dual PI3K/mTOR Inhibitor, XL765, suppresses glioblastoma growth by inducing ER stress-dependent apoptosis
Hang Zhao et al.
ONCOTARGETS AND THERAPY (2019)
Fibroblast Growth Factor Receptor Functions in Glioblastoma
Ana Jimenez-Pascual et al.
CELLS (2019)
Second Generation mTOR Inhibitors as a Double-Edged Sword in Malignant Glioma Treatment
Dennis Heinzen et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Receptor tyrosine kinase expression in high-grade gliomas before and after chemoradiotherapy
Kuanyu Wang et al.
ONCOLOGY LETTERS (2019)
Autophagy induction impairs Wnt/beta-catenin signalling through beta-catenin relocalisation in glioblastoma cells
Barbara Colella et al.
CELLULAR SIGNALLING (2019)
Emerging functions of the EGFR in cancer
Sara Sigismund et al.
MOLECULAR ONCOLOGY (2018)
A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913
Prakash Chinnaiyan et al.
NEURO-ONCOLOGY (2018)
Role of Microenvironment in Glioma Invasion: What We Learned from In Vitro Models
Ivana Manini et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Mechanisms of receptor tyrosine kinase activation in cancer
Zhenfang Du et al.
MOLECULAR CANCER (2018)
mTOR inhibition in glioblastoma: requiem for a dream?
Sam Babak et al.
NEURO-ONCOLOGY (2018)
Oxymatrine induces cell cycle arrest and apoptosis and suppresses the invasion of human glioblastoma cells through the EGFR/PI3K/Akt/mTOR signaling pathway and STAT3
Zhibo Dai et al.
ONCOLOGY REPORTS (2018)
P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice
Jing Wang et al.
PHARMACOLOGICAL RESEARCH (2018)
New Multitarget Approaches in the War Against Glioblastoma: A Mini-Perspective
Simona Sestito et al.
FRONTIERS IN PHARMACOLOGY (2018)
Major Challenges and Potential Microenvironment-Targeted Therapies in Glioblastoma
Ali S. Arbab et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development
Hua-fu Zhao et al.
MOLECULAR CANCER (2017)
A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies
Trisha M. Wise-Draper et al.
TARGETED ONCOLOGY (2017)
The structure-guided discovery of osimertinib: the first US FDA approved mutant selective inhibitor of EGFR T790M
Sam Butterworth et al.
MEDCHEMCOMM (2017)
The molecular mechanisms of chemoresistance in cancers
Hua-Chuan Zheng
ONCOTARGET (2017)
Glioblastoma targeted therapy: updated approaches from recent biological insights
M. Touat et al.
ANNALS OF ONCOLOGY (2017)
mTOR Signaling in Growth, Metabolism, and Disease (vol 168, pg 960, 2017)
Robert A. Saxton et al.
CELL (2017)
Insulin-mediated signaling promotes proliferation and survival of glioblastoma through Akt activation
Yuanying Gong et al.
NEURO-ONCOLOGY (2016)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
Peter Ballard et al.
CLINICAL CANCER RESEARCH (2016)
PQ401, an IGF-1R inhibitor, induces apoptosis and inhibits growth, proliferation and migration of glioma cells
Xiang Zhou et al.
JOURNAL OF CHEMOTHERAPY (2016)
PI3K p110β isoform synergizes with JNK in the regulation of glioblastoma cell proliferation and migration through Akt and FAK inhibition
Hua-Fu Zhao et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2016)
Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats
I. A. Netland et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR
Timothy P. Heffron et al.
ACS MEDICINAL CHEMISTRY LETTERS (2016)
PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
Xiaoman Li et al.
ONCOTARGET (2016)
A first-in-human phase 1 study to evaluate the brain penetrant PI3K/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma.
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells
Zhiyun Yu et al.
CANCER LETTERS (2015)
Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma
Jennifer R. Brown et al.
CLINICAL CANCER RESEARCH (2015)
Recent advances in targeted therapy for glioblastoma
Shivani Mittal et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2015)
Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma
Ursula Matulonis et al.
GYNECOLOGIC ONCOLOGY (2015)
NVP-BKM120 potentiates apoptosis in tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cell lines via upregulation of Noxa and death receptor 5
Kimberly A. Foster et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors
Johanna C. Bendell et al.
INVESTIGATIONAL NEW DRUGS (2015)
The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
Paul Foster et al.
MOLECULAR CANCER THERAPEUTICS (2015)
GSK1838705A, an IGF-1R inhibitor, inhibits glioma cell proliferation and suppresses tumor growth in vivo
Xiang Zhou et al.
MOLECULAR MEDICINE REPORTS (2015)
Autophagy induction impairs migration and invasion by reversing EMT in glioblastoma cells
Myriam Catalano et al.
MOLECULAR ONCOLOGY (2015)
Phase II study of PX-866 in recurrent glioblastoma
Marshall W. Pitz et al.
NEURO-ONCOLOGY (2015)
Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2015)
BMS-536924, an ATP-competitive IGF-1R/IR inhibitor, decreases viability and migration of temozolomide-resistant glioma cells in vitro and suppresses tumor growth in vivo
Qiao Zhou
ONCOTARGETS AND THERAPY (2015)
Recent advances in targeted therapy for glioblastoma
Shivani Mittal et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2015)
Glioma
Michael Weller et al.
NATURE REVIEWS DISEASE PRIMERS (2015)
Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma
Emily Padfield et al.
FRONTIERS IN ONCOLOGY (2015)
Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer
Sara Tolaney et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
RIST: A potent new combination therapy for glioblastoma
Lisa Nonnenmacher et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma
David A. Reardon et al.
NEURO-ONCOLOGY (2015)
EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma
L. Li et al.
ONCOGENE (2015)
OPINION Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma
Frank B. Furnari et al.
NATURE REVIEWS CANCER (2015)
Current management of advanced melanoma: a transformed landscape
David E. Gyorki et al.
ANZ JOURNAL OF SURGERY (2014)
Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma
Carlos Rodrigo Gil del Alcazar et al.
CLINICAL CANCER RESEARCH (2014)
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors
Kyriakos P. Papadopoulos et al.
CLINICAL CANCER RESEARCH (2014)
Dual targeting of glioblastoma multiforme with a proteasome inhibitor (Velcade) and a phosphatidylinositol 3-kinase inhibitor (ZSTK474)
Lehang Lin et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
PI3K and Bcl-2 Inhibition Primes Glioblastoma Cells to Apoptosis through Downregulation of Mcl-1 and Phospho-BAD
Fresia Pareja et al.
MOLECULAR CANCER RESEARCH (2014)
Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway
Peiwen Yu et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2014)
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab for Newly Diagnosed Glioblastoma Reply
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
mTORC2 in the center of cancer metabolic reprogramming
Kenta Masui et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2014)
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A. E. Cross et al.
CANCER DISCOVERY (2014)
Pazopanib for the treatment of advanced renal cell cancer
Bernard Escudier et al.
EXPERT OPINION ON ORPHAN DRUGS (2014)
Role of Receptor Tyrosine Kinases and Their Ligands in Glioblastoma
Estefania Carrasco-Garcia et al.
CELLS (2014)
Inhibition of Phosphatidylinositol 3-Kinase/AKT Signaling by NVP-BKM120 Promotes ABT-737-Induced Toxicity in a Caspase-Dependent Manner through Mitochondrial Dysfunction and DNA Damage Response in Established and Primary Cultured Glioblastoma Cells
Esther P. Jane et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Distribution of the Phosphatidylinositol 3-Kinase Inhibitors Pictilisib (GDC-0941) and GNE-317 in U87 and GS2 Intracranial Glioblastoma Models-Assessment by Matrix-Assisted Laser Desorption Ionization Imaging
Laurent Salphati et al.
DRUG METABOLISM AND DISPOSITION (2014)
Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Combined Targeting of PDK1 and EGFR Triggers Regression of Glioblastoma by Reversing the Warburg Effect
Kiran Kumar Velpula et al.
CANCER RESEARCH (2013)
The Somatic Genomic Landscape of Glioblastoma
Cameron W. Brennan et al.
CELL (2013)
Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance
Arman Jahangiri et al.
CLINICAL CANCER RESEARCH (2013)
Synthesis and biological evaluation of novel phosphatidylinositol 3-kinase inhibitors: Solubilized 4-substituted benzimidazole analogs of 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474)
Gordon W. Rewcastle et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2013)
Therapeutic targeting of EGFR-activated metabolic pathways in glioblastoma
Qinglei Gao et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
The novel phosphoinositide 3-kinasemammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor
Takako Sano et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
RTOG 0211: A Phase 1/2 Study of Radiation Therapy With Concurrent Gefitinib for Newly Diagnosed Glioblastoma Patients
Arnab Chakravarti et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways
Timothy A. Yap et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Development of PI3K inhibitors: lessons learned from early clinical trials
Jordi Rodon et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
Tracy T. Batchelor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Radiosensitization of Glioblastoma Cell Lines by the Dual PI3K and mTOR Inhibitor NVP-BEZ235 Depends on Drug-Irradiation Schedule
Sebastian Kuger et al.
TRANSLATIONAL ONCOLOGY (2013)
Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment
X. Sui et al.
CELL DEATH & DISEASE (2013)
Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives
Maria Vittoria Dieci et al.
CANCER DISCOVERY (2013)
Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1
Maria Giovanna Francipane et al.
ONCOTARGET (2013)
Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited
Karl H. Plate et al.
ACTA NEUROPATHOLOGICA (2012)
Antitumor Activity of NVP-BKM120-A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells
Dimpy Koul et al.
CLINICAL CANCER RESEARCH (2012)
The catalytic phosphoinositol 3-kinase isoform p110δ is required for glioma cell migration and invasion
Sze Ki Luk et al.
EUROPEAN JOURNAL OF CANCER (2012)
Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib
Paula Kinsella et al.
EXPERIMENTAL CELL RESEARCH (2012)
Nimotuzumab treatment of malignant gliomas
Udo Bode et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2012)
Emerging insights into the molecular and cellular basis of glioblastoma
Gavin P. Dunn et al.
GENES & DEVELOPMENT (2012)
Selective Class I Phosphoinositide 3-Kinase Inhibitors: Optimization of a Series of Pyridyltriazines Leading to the Identification of a Clinical Candidate, AMG 511 (vol 55, pg 7796, 2012)
Mark H. Norman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma
Enrico Franceschi et al.
NEURO-ONCOLOGY (2012)
Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors
Anindita Chakrabarty et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055
Gayle Marshall et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2011)
Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma
Ho-Shin Gwak et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study
John F. de Groot et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Discovery of 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)-phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a Potent, Selective, and Orally Available Mammalian Target of Raparnycin (mTOR) Inhibitor for Treatment of Cancer
Qingsong Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
mTOR: from growth signal integration to cancer, diabetes and ageing
Roberto Zoncu et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2011)
Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide
Gautam Prasad et al.
NEURO-ONCOLOGY (2011)
Neuromuscular junction toxicity with tandutinib induces a myasthenic-like syndrome
T. J. Lehky et al.
NEUROLOGY (2011)
The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model of PIK3CA Wild-Type Colorectal Cancer
Jatin Roper et al.
PLOS ONE (2011)
The NFκB pathway: a therapeutic target in glioblastoma
Lorena Nogueira et al.
ONCOTARGET (2011)
Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis
Tao Xu et al.
BMC CANCER (2010)
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Roel G. W. Verhaak et al.
CANCER CELL (2010)
AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
Christine M. Chresta et al.
CANCER RESEARCH (2010)
Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
Martin L. Sos et al.
CANCER RESEARCH (2010)
Increased expression of Akt2 and activity of PI3K and cell proliferation with the ascending of tumor grade of human gliomas
Guangxiu Wang et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2010)
Emerging Concepts for the Treatment of Hematological Malignancies with Therapeutic Monoclonal Antibodies
Aude-Helene Capietto et al.
CURRENT DRUG TARGETS (2010)
The PI3K Pathway As Drug Target in Human Cancer
Kevin D. Courtney et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma
David A. Reardon et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Regulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and Stress
Shomit Sengupta et al.
MOLECULAR CELL (2010)
mToR signaling and drug development in cancer
Janet Dancey
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
The emerging mechanisms of isoform-specific PI3K signalling
Bart Vanhaesebroeck et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma
Shucheng Yin et al.
NEURO-ONCOLOGY (2010)
Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma
Dimpy Koul et al.
NEURO-ONCOLOGY (2010)
Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells
Jun Sunayama et al.
NEURO-ONCOLOGY (2010)
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
Sith Sathornsumetee et al.
NEURO-ONCOLOGY (2010)
Changes in Vascular Permeability and Expression of Different Angiogenic Factors Following Anti-Angiogenic Treatment in Rat Glioma
Meser M. Ali et al.
PLOS ONE (2010)
Crosstalk Between the PI3K/mTOR and MEK/ERK Pathways Involved in the Maintenance of Self-Renewal and Tumorigenicity of Glioblastoma Stem-Like Cells
Jun Sunayama et al.
STEM CELLS (2010)
Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs
Ben Markman et al.
ONCOTARGET (2010)
Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
B. Neyns et al.
ANNALS OF ONCOLOGY (2009)
Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities
Helmout Modjtahedi et al.
ANTI-CANCER DRUGS (2009)
Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma
D. A. Reardon et al.
BRITISH JOURNAL OF CANCER (2009)
A Vascular Normalization Index as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients
A. Gregory Sorensen et al.
CANCER RESEARCH (2009)
Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy
John M. L. Ebos et al.
CLINICAL CANCER RESEARCH (2009)
Optimal targeting of the mTORC1 kinase in human cancer
Heidi A. Lane et al.
CURRENT OPINION IN CELL BIOLOGY (2009)
Cell type specificity of PI3K signaling in Pdk1-and Pten-deficient brains
Nader Chalhoub et al.
GENES & DEVELOPMENT (2009)
mTOR signaling at a glance
Mathieu Laplante et al.
JOURNAL OF CELL SCIENCE (2009)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
Florence I. Raynaud et al.
MOLECULAR CANCER THERAPEUTICS (2009)
FDA Drug Approval Summary: Bevacizumab (Avastin (R)) as Treatment of Recurrent Glioblastoma Multiforme
Martin H. Cohen et al.
ONCOLOGIST (2009)
Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis
Haihao Zhu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Effects of oncogenic p110α subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase
Jeffrey D. Carson et al.
BIOCHEMICAL JOURNAL (2008)
Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms
Li Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-Deficient glioblastoma
Tim F. Cloughesy et al.
PLOS MEDICINE (2008)
The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures
Amy L. Howes et al.
MOLECULAR CANCER THERAPEUTICS (2007)
PIKE-A is a proto-oncogene promoting cell growth, transformation and invasion
X. Liu et al.
ONCOGENE (2007)
AKT/PKB signaling: Navigating downstream
Brendan D. Manning et al.
CELL (2007)
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Jeffrey A. Engelman et al.
NATURE REVIEWS GENETICS (2006)
Effects of cotransfection of antisense-EGFR and wild-type PTEN cDNA on human glioblastoma cells
Xin-Xia Tian et al.
NEUROPATHOLOGY (2006)
Genetic alteration and expression of the phosphoinositol-3-kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas
CB Knobbe et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2005)
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
SM Chang et al.
INVESTIGATIONAL NEW DRUGS (2005)
Gene expression profiling and genetic markers in glioblastoma survival
JN Rich et al.
CANCER RESEARCH (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2
A Garami et al.
MOLECULAR CELL (2003)
Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis
AM Joy et al.
JOURNAL OF CELL SCIENCE (2003)
Ligand-induced, receptor-mediated dimerization and activation of EGF receptor
J Schlessinger
CELL (2002)
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
K Inoki et al.
NATURE CELL BIOLOGY (2002)
The phosphatidylinositol 3-kinase-AKT pathway in human cancer
I Vivanco et al.
NATURE REVIEWS CANCER (2002)
Epidermal growth factor receptor and Ink4a/Arf:: Convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis
RM Bachoo et al.
CANCER CELL (2002)
PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy
LD Mayo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
The EGF receptor family as targets for cancer therapy
J Mendelsohn et al.
ONCOGENE (2000)
Cell signaling by receptor tyrosine kinases
J Schlessinger
CELL (2000)
Vasculogenic mimicry and tumor angiogenesis
R Folberg et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Share Paper
